Michael Engsig joined Vaccibody in March 2017. He is a broadly anchored pharmaceutical professional with extensive experience from early-stage drug discovery to late-stage development and product launches in biotech and pharma and across all major geographical areas, e.g. with Takeda and Nycomed. He holds a civil engineering (MSc) degree in chemistry specializing in biotechnology from the Technical University of Denmark, and a Graduate Diploma in Business Administration (HD) in organization and leadership from Copenhagen Business School (CBS).
Agnete B. Fredriksen is a co-founder of Vaccibody. Her focus is on developing vaccines from idea to clinical development, having had prior roles at Affitech AS and Medinnova AS. She is the author of numerous scientific papers in the field of immunology, immunotherapy and vaccines, and has been awarded several patents in the field of immunotherapy. She holds an MSc and a Ph.D. from the Institute of Immunology, Rikshospitalet Medical Center in Oslo, where she designed and developed the first Vaccibody vaccine molecules. She received the King’s Gold Medal of Merit for her Ph.D. thesis describing vaccibodies.
Mette Husbyn joined Vaccibody in 2017. Her professional experience spans CMC, drug development through all clinical stages from early research to NDA/MAA filings, including regulatory filings within both the antimicrobial and immune oncology programs, as well as diagnostic imaging. Past employments include Lytix Biopharma, Nycomed Pharma, Amersham Health and GE Healthcare. She holds a Ph.D. in peptide chemistry from the University of Oslo.
Siri Torhaug joined Vaccibody as Chief Medical Officer in January 2020. She has broad experience in clinical development and translational research. Furthermore, she has extensive experience in scientific and medical affairs covering relevant tumor areas, R&D and general management of cancer drug development as well as product launches and life cycle management for several oncology products. Past employments include Oslo University Hospital (Radiumhospitalet), one of the premier oncology hospitals in Europe, as well as Novartis and AstraZeneca. She is a medical doctor and a certified clinical specialist in oncology.
Harald Gurvin joined Vaccibody in May 2021 as CFO. Harald has a long career in the field of finance, most recently as CFO in Flex LNG, a company owning and operating LNG carriers and listed on both the New York Stock Exchange (NYSE) and the Oslo Stock Exchange. Prior to Flex LNG, he was CFO in SFL Corporation Limited, a leading international ship-owning company listed on the NYSE.
He holds a MSc in Shipping, Trade and Finance from CASS Business School and a MSc in Marine Engineering and Naval Architecture from the Norwegian University of Science and Technology.
Caspar Foghsgaard joined Vaccibody in November 2018 as Director Business Development. He holds a MSc in Management from University of Surrey and a Bsc (Hons.) in Chemistry with Biological Chemistry from the University of St Andrews.
Caspar’s professional experience spans from business development and strategy in Novozymes A/S to being an independent consultant to biotech companies. His experience includes diverse transactions within business development, fundraising and mergers & acquisitions.
Mie Kvisle joined Vaccibody as Chief Human Resources Officer in January 2021. She has 20 years of experience in developing people and organizations. Mie’s career has its outset in the Nordics including 7 years in Elkjøp Nordic as Head of Organization Development.
She is passionate about people and organizational development through leadership, culture, and digitalization in a sustainable society. Mie is specialized in performance psychology and has worked as a Mental Trainer for the Men’s Norwegian National Handball team for several years.